SCHEMBL3774201

SCHEMBL3774201

O=C(Cc1ccc(F)cc1)N1CCN(CC(=O)N2CCN(C3CCC3)CC2)CC1

nearest known ligand 0.61

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.61
▸ KDM4E B2RXH2 2/20 0.61
▸ PKM P14618 1/20 0.55
▸ POLB P06746 1/20 0.53
▸ ME2 P23368 1/20 0.52
▸ ME1 P48163 1/20 0.52
▸ ME3 Q16798 1/20 0.52
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ HRH3 Q9Y5N1 4/20 0.49
▸ MEN1 O00255 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ MLNR O43193 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3767486 0.88 ALDH1A1 (0.61) ALDH1A1KDM4EPOLBSMN1; SMN2MEN1
SCHEMBL3770031 0.88 KDM4E (0.61) ALDH1A1KDM4EME2ME1ME3
SCHEMBL3775691 0.88 ALDH1A1 (0.61) ALDH1A1KDM4ESMN1; SMN2HRH3MEN1
SCHEMBL3770129 0.88 ALDH1A1 (0.80) ALDH1A1KDM4EME2ME1ME3
SCHEMBL3767613 0.87 ALDH1A1 (0.57) ALDH1A1KDM4EME2ME1ME3
SCHEMBL3768082 0.86 KDM4E (0.59) ALDH1A1KDM4EPOLBHRH3MEN1
SCHEMBL3772641 0.86 ALDH1A1 (0.69) ALDH1A1KDM4ESMN1; SMN2HRH3MAPT
SCHEMBL3770102 0.85 MAPT (0.59) ALDH1A1KDM4EPOLBME2ME1
SCHEMBL3774012 0.85 L3MBTL1 (0.61) ALDH1A1KDM4EPOLBHRH3MEN1
SCHEMBL3777237 0.85 SMN1; SMN2 (0.64) ALDH1A1KDM4ESMN1; SMN2KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 — — US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 — — US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 — — US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 — — US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 — — US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 — — US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 ALDH1A1 1210/4885KDM4E 534/4885PKM 219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback